MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, SLS had $57,907K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$57,907K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from warrant inducement...
    • Proceeds from issuance of common...
    • Proceeds from the exercise of co...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses and other curre...
    • Prepaid expenses and other asset...
    • Others

Cash Flow
2025-12-31
Net loss
-26,863
Non-cash stock-based compensation
1,956
Non-cash lease expense
597
Prepaid expenses and other assets
968
Accounts payable
-535
Accrued expenses and other current liabilities
-1,941
Operating lease liabilities
-635
Net cash used in operating activities
-28,389
Proceeds from warrant inducements, net of issuance costs
51,042
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs
23,051
Proceeds from the exercise of common stock warrants and pre-funded warrants
12,618
Proceeds from employee stock plan purchases
112
Tax withholding on vesting of restricted stock units
527
Net cash provided by financing activities
86,296
Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents
57,907
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of year
13,986
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of year
71,893
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from warrantinducements, net of issuance...$51,042K Proceeds from issuance ofcommon stock, common...$23,051K Proceeds from theexercise of common stock...$12,618K Proceeds from employeestock plan purchases$112K Net cash provided byfinancing activities$86,296K Canceled cashflow$527K Net increase incash, cash...$57,907K Canceled cashflow$28,389K Tax withholding onvesting of restricted...$527K Non-cash stock-basedcompensation$1,956K Non-cash lease expense$597K Net cash used inoperating activities-$28,389K Canceled cashflow$2,553K Net loss-$26,863K Accrued expenses andother current...-$1,941K Prepaid expenses andother assets$968K Operating leaseliabilities-$635K Accounts payable-$535K

SELLAS Life Sciences Group, Inc. (SLS)

SELLAS Life Sciences Group, Inc. (SLS)